Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.55 |
| ▸ | NT5E | P21589 | 1/20 | 0.53 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.53 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.53 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.51 |
| ▸ | IMPDH2 | P12268 | 5/20 | 0.51 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.51 |
| ▸ | TGM2 | P21980 | 1/20 | 0.50 |
| ▸ | HINT1 | P49773 | 1/20 | 0.49 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2218829 | 0.93 | HPGD (0.57) | HPGDNT5ETAS1R3TAS1R1ADORA1 | |
| SCHEMBL888070 | 0.93 | HPGD (0.57) | HPGDNT5ETAS1R3TAS1R1ADORA1 | |
| SCHEMBL30670299 | 0.92 | HPGD (0.55) | HPGDNT5ETAS1R3TAS1R1IMPDH2 | |
| SCHEMBL17438077 | 0.91 | HPGD (0.57) | HPGDNT5ETAS1R3TAS1R1ADORA1 | |
| SCHEMBL15328981 | 0.90 | HPGD (0.55) | HPGDNT5ETAS1R3TAS1R1ADORA1 | |
| SCHEMBL23149828 | 0.89 | NT5E (0.55) | HPGDNT5ETAS1R3TAS1R1ADORA1 | |
| SCHEMBL15328996 | 0.88 | HPGD (0.53) | HPGDNT5ETAS1R3TAS1R1ADORA1 | |
| SCHEMBL2220159 | 0.87 | ADORA1 (0.67) | HPGDNT5ETAS1R3TAS1R1ADORA1 | |
| SCHEMBL1477429 | 0.87 | ADORA1 (0.67) | HPGDNT5ETAS1R3TAS1R1ADORA1 | |
| SCHEMBL94114 | 0.87 | NT5E (0.64) | HPGDNT5ETAS1R3TAS1R1ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260002160-A1 | SIRNA TARGETING AND REGULATING PCSK9 GENE EXPRESSION AND USE THEREOF | HANGZHOU TIANLONG PHARMACEUTICAL CO LTD (CN) | 2026-01-01 | — | — | US | disclosed |
| EP-4578948-A1 | SIRNA FOR TARGETED REGULATION OF PCSK9 GENE EXPRESSION, AND USE THEREOF | Hangzhou Tianlong Pharmaceutical Co., Ltd. (CN) | 2025-07-02 | — | — | EP | disclosed |
| WO-2025097633-A1 | SIRNA FOR TARGETED REGULATION OF PCSK9 GENE EXPRESSION, AND USE THEREOF | 杭州天龙药业有限公司 | 2025-05-15 | — | — | WO | disclosed |
| CN-118147134-B | SiRNA for targeted regulation and control of PCSK9 gene expression and application thereof | 北京悦康科创医药科技股份有限公司 | 2025-02-25 | — | — | CN | disclosed |
| CN-117210468-B | SiRNA for targeted regulation and control of PCSK9 gene expression and application thereof | 北京悦康科创医药科技股份有限公司 | 2024-02-20 | — | — | CN | disclosed |
| CN-117210468-A | SiRNA for targeted regulation and control of PCSK9 gene expression and application thereof | 北京悦康科创医药科技股份有限公司 | 2023-12-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260002160-A1 | SIRNA TARGETING AND REGULATING PCSK9 GENE EXPRESSION AND USE THEREOF | PCSK9, METTL16, AGO2 | HPGD 4661/4885NT5E 1627/4885TAS1R3 2862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.